A #cancer diagnosis can be an emotional and confusing time. Caris looks at cancer on a molecular level and works with patients and #oncologists to discover more personalized treatment options. Learn more about Caris testing: ow.ly/AHzr50OS4rl

Caris Life Sciences is pleased to announce the appointment of Dave Fredrickson, Executive Vice President of the Oncology Business Unit at AstraZeneca PLC, to our Board of Directors. Learn more: carislifesciences.com/about/news-and…

Caris President David Spetzler, MS, PhD, MBA shares how we’re transforming cancer care through tech and innovation, and his personal connection to a relentless pursuit of improved patient care. Learn more: ow.ly/gj4K50T6NSo

Connect with Caris at this year's World CB & CDx Summit in Boston! Our team is ready to discuss how to stay ahead in oncology with innovative approaches to biomarker research, clinical strategies, and more. Visit us at booth 16! ow.ly/JR0F50T85JF #WorldCDx

#ProstateCancer diversity revealed: AR and neuroendocrine signatures. Yu-Wei Chen, MD, MS UC San Diego Health Moores Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber to discuss his research using the #Caris database underscoring the potential of molecular diagnostics > bit.ly/3Z2dX5z Caris Life Sciences

Connect with Caris at Booth 16. Dive into the latest trends in oncology with our experts. We're here to help advance biomarker research and clinical strategies from small molecules to large biologics. Don't miss out! ow.ly/FOm050T85Oz #WorldCDx

Attending World CB & CDx? Join David Spetzler’s presentation, “Future Forward: From Advanced Diagnostics to Therapeutic Discovery with a Single Comprehensive Assay.” ow.ly/ak3u50T85T1 #WorldCDx

Caris and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present seven studies across a wide range of tumor types during #ESMO24. Learn more: ow.ly/lhJ850TeVmh

Networking at World CB & CDx? Meet with our team, hear the latest information on our current product offerings, and learn about the most advanced approach to precision medicine. Visit booth 16. ow.ly/v7f450TfTyp #WorldCDx

Milan Radovich, PhD, highlighted how comprehensive assays using WES, WTS, and IHC testing set the stage for future diagnostics and therapeutic breakthroughs. ow.ly/5NOJ50Th5EG #WorldCDx

Connect with Caris Life Sciences at IASLC #WCLC24 and dive into our latest research. Explore our five posters and learn about our innovative molecular profiling offerings. Join us at Booth 408. ow.ly/A1wk50ThLTR

What is the role of NEDD9 in lung cancer? Hear Dr. Julia Judd from Fox Chase Cancer Center discuss the impact of NEDD9 gene expression on outcomes in 1,800+ cases of aggressive dual KRAS- and STK11-mutant NSCLC. #WCLC24 carislifesciences.com/iaslc-wclc-202…

Does HER3 expression have an impact on non-EGFR-mutant NSCLC? Join Dr. Brinda Gupta from Georgetown Lombardi as she explores HER3 expression in a cohort of >52k NSCLC samples from Caris. #WCLC24 ow.ly/Sih450TilP0

Network with leaders in lung cancer research during IASLC #WCLC24! Caris Life Sciences is showcasing groundbreaking advancements and highlighting our comprehensive molecular profiling options. Visit us at Booth 408.

Cell-surface protein SEZ6 is a potential ADC target in SCLC and neuroendocrine (NE) tumors. Hear @JenniferMarksMD from Georgetown Lombardi discuss molecular profiles of SEZ6 and other relevant biomarkers in 3,500+ SCLC and NE tumors from Caris. #WCLC24

What treatment strategy is most effective in advanced large cell neuroendocrine tumors (LCNEC)? Amin Nassar, MD from Yale Department of Immunobiology shows that chemo and immunotherapy have similar effectiveness, but IO is significantly less toxic. #WCLC24

Does the immune environment affect the effectiveness of immunotherapy in the rare lung cancer LUAS? Hear Dr. Matthew Lee Montefiore Health System Albert Einstein College of Medicine - Official discuss how the LUAS immune environment differs from other classes of NSCLC. #WCLC24

Caris Life Sciences recently showcased our latest research through poster presentations in collaboration with leading cancer centers at the IASLC World Conference on Lung Cancer.